文献速递泌尿生殖与妇科肿瘤放疗

局限性前列腺癌的极限大分割立体定向放疗:根据经尿道前列腺电切术史评估疗效与晚期泌尿系统毒性

Extreme hypofractionated stereotactic radiotherapy for localized prostate Cancer: Efficacy and late urinary toxicity according to transurethral resection of the prostate history.
PubMed 文献 · Clin Transl Radiat Oncol · 2024-04-18

这项回顾性研究纳入2010至2020年在Oscar Lambret中心接受CyberKnife™ SBRT作为初次放疗的141例局限性前列腺腺癌患者,处方剂量为36.25 Gy分5次。5年无生化复发生存率为72%,晚期≥2级泌尿系统毒性5年累积发生率为20.6%;多因素分析显示经尿道前列腺电切术史与晚期≥2级泌尿系统毒性显著相关(OR=3.06)。

要点

  • 141例局限性前列腺癌患者接受36.25 Gy分5次SBRT,5年bRFS为72%、OS为82%。
  • 晚期≥2级泌尿系统毒性5年累积发生率为20.6%,≥2级晚期毒性共29例。
  • 经尿道前列腺电切术史与晚期≥2级泌尿系统毒性显著相关(OR=3.06,95%CI 1.05-8.86,P=0.04)。

核心结论

  • 极限大分割SBRT对局限性前列腺癌有效,晚期毒性风险低。
  • 经尿道前列腺电切术史与更高的晚期泌尿系统毒性风险相关。
  • 这些发现可能有助于优化接受该方案患者的治疗管理,尤其是具有经尿道前列腺电切术史者。

研究设计与样本

  • 回顾性研究,纳入2010年至2020年在Oscar Lambret中心接受CyberKnife™ SBRT作为初次放疗的141例连续性局限性前列腺腺癌患者。
  • 处方剂量为36.25 Gy分5次。
  • 急性和晚期毒性按CTCAE第5.0版分级。
  • 采用Kaplan-Meier法估计无生化复发生存率和总生存率,采用Kalbfleisch-Prentice法估计生化复发累积发生率。

主要发现

  • 纳入患者中13.5%有经尿道前列腺电切术史。
  • 中位随访48个月。
  • 5年无生化复发生存率为72%(95%CI:61-81),生化复发累积发生率为7%(95%CI:3-14),总生存率为82%(95%CI:73-89)。
  • 29例患者发生至少一次≥2级晚期毒性;泌尿生殖系统毒性29例,包括3例慢性血尿,和/或胃肠道毒性1例。
  • 晚期≥2级泌尿系统毒性5年累积发生率为20.6%(95%CI:13.9-28.1)。

关键数值与推荐

  • 处方剂量为36.25 Gy分5次。
  • 毒性分级采用CTCAE第5.0版。
  • 5年无生化复发生存率为72%(95%CI:61-81)。
  • 5年生化复发累积发生率为7%(95%CI:3-14)。
  • 5年总生存率为82%(95%CI:73-89)。

临床怎么用

  • 作者认为,这些发现可能有助于优化接受该方案患者的治疗管理,尤其是具有经尿道前列腺电切术史者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Extreme hypofractionated stereotactic body radiotherapy (SBRT) is a therapeutic alternative for localized low- or intermediate-risk prostate cancer. Despite the availability of several studies, the toxicity profile of SBRT has not been comprehensively described. This real-world evidence study assessed the efficacy and toxicities associated with this regimen, and potential prognosis factors for genitourinary toxicities. MATERIALS AND METHODS: This retrospective study included 141 consecutive patients with localized prostatic adenocarcinoma treated with CyberKnife™ SBRT, as primary irradiation, at the Oscar Lambret Center between 2010 and 2020. The prescribed dose was 36.25 Gy in 5 fractions. Acute and late toxicities were graded according to the CTCAE (version 5.0). Biochemical recurrence-free survival (bRFS) and overall survival (OS) were estimated using the Kaplan-Meier method. The cumulative incidence of biochemical recurrence (cBR) was estimated using the Kalbfleisch-Prentice method. RESULTS: Among the included patients, 13.5 % had a history of transurethral resection of the prostate (TURP). The median follow-up was 48 months. At 5 years, bRFS, cBR, and OS were 72 % (95 %CI: 61-81), 7 % (95 %CI: 3-14), and 82 % (95 %CI: 73-89), respectively. Twenty-nine patients experienced at least one late toxicity of grade ≥ 2; genitourinary (N = 29), including 3 cases of chronic hematuria, and/or gastrointestinal (N = 1). The cumulative incidence of late urinary toxicity of grade ≥ 2 was 20.6 % at 5 years (95 %CI: 13.9-28.1). Multivariate analysis revealed that a history of TURP was significantly associated with late urinary toxicity of grade ≥ 2, after adjusting for clinical target volume (Odds Ratio = 3.06; 95%CI: 1.05-8.86; P = 0.04). CONCLUSION: Extreme hypofractionated SBRT is effective for localized prostate cancer with a low risk of late toxicity. A history of TURP is associated with a higher risk of late urinary toxicity. These findings may contribute to the optimal management of patients treated with this regimen, particularly those with a history of TURP.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Galienne M, Risbourg S, Lacornerie T, et al. Extreme hypofractionated stereotactic radiotherapy for localized prostate Cancer: Efficacy and late urinary toxicity according to transurethral resection of the prostate history. Clin Transl Radiat Oncol. 2024. PMID: 38681137. doi:10.1016/j.ctro.2024.100779

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。